Table 3 Comparison of pathologic characteristics between patients in group 1 and patients with stage IIA pulmonary adenocarcinoma
From: The importance of the lepidic component as a prognostic factor in stage I pulmonary adenocarcinoma
Group 1 | Stage IIA | p value | |
|---|---|---|---|
Tumor size, cm (±SD) | 2.2 (±0.9)cm | 3.0 (±1.3)cm | 0.005 |
Pleural invasion, n (%) | 23 (31.9 %) | 9 (40.9 %) | 0.298 |
Lymphatic invasion, n (%) | 21 (29.2 %) | 20 (87.0 %) | <0.001 |
Vascular invasion, n (%) | 9 (12.5 %) | 11 (47.8 %) | 0.001 |
Differentiation | 0.534 | ||
Mild, n (%) | 15 (20.5 %) | 4 (17.4 %) | |
Moderate, n (%) | 49 (67.1 %) | 14 (60.9 %) | |
Poor, n (%) | 9 (12.3 %) | 5 (21.7 %) | |
EGFR mutation | 75.4 % | 76.2 % | 0.597 |
Micropapillary component, % (±SD) | 3.4 (±9.4)% | 5.5 (±8.9)% | 0.378 |
Solid component, % (±SD) | 15.1 (±27.9)% | 15.7 (±29.5)% | 0.936 |
Acinar component, % (±SD) | 49.0 (±37.7)% | 48.3 (±28.5)% | 0.927 |
Papillary component, % (±SD) | 23.84 (±33.5)% | 17.1 (±22.7)% | 0.296 |
Lepidic component, % (±SD) | 4.4 (±4.6)% | 9.9 (±15.0)% | 0.095 |